DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans. DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.
See also DOx (psychedelics) DOBU DOEF DOPR DOTFM 2C-TFE 2C-T-21 2C-T-28
References
External links DOPF - Isomer Design